WAM
ALXN

Wolverine Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Wolverine Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-60
Closed -$1K – 1729
2015
Q4 		$1K Hold
60
– – ﹤0.01% 1649
2015
Q3 		$40K Hold
60
– – ﹤0.01% 1325
2015
Q2 		$24K Hold
60
– – ﹤0.01% 1456
2015
Q1 		$41K Buy
+60
New +$10.9K ﹤0.01% 1302
2014
Q4 		– Sell
-82
Closed -$77K – 2597
2014
Q3 		$77K Buy
+82
New +$13.5K ﹤0.01% 1390
2014
Q1 		– Sell
-71
Closed -$22K – 2881
2013
Q4 		$22K Hold
71
– – ﹤0.01% 2045
2013
Q3 		$126K Buy
+71
New +$7.79K ﹤0.01% 1366

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Wolverine Asset Management's ALXN Position: Q3 2021 in Review

Wolverine Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 37,926 shares — an estimated $6.97M sold.

Wolverine Asset Management first reported a position in ALXN in Q2 2013 and held it in 14 quarters. The position peaked at $6.97M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Wolverine Asset Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Wolverine Asset Management sold 37,926 Alexion Pharmaceuticals shares in Q3 2021, an estimated $6.97M.
  • Wolverine Asset Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 14 quarters.
  • Wolverine Asset Management's Alexion Pharmaceuticals position peaked at $6.97M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Wolverine Asset Management's 13F filing for Q3 2021, filed 12 Nov 2021.